Trial
NCT02709889
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
AbbVie
Collaborators
—
Condition
Malignant Melanoma
Intervention
Rovalpituzumab tesirine
Why stopped
Strategic considerations
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-19